News | November 13, 2006

FDA Says Tamiflu Patients Need Monitoring

More than 100 recent cases of delirium, hallucinations and other unusual psychiatric behavior in Japanese patients treated with Tamiflu should have parents watching for similar reactions when treating their children with the flu drug. That's the new advice from the Food and Drug Administration in adding a new precaution to the label of the influenza drug, prescribed about 2 million times a year in the U.S.

The FDA updated the label after receiving the 103 reports of abnormal behavior, most of which involved children in Japan. Japan uses more Tamiflu than any other country in the world, with more than 30 million prescriptions since 2001. It's been prescribed about 8 million times in the U.S. since 1999.

The FDA said a relationship between the drug and the behavior had not been established and that the updated label was "intended to mitigate a potential risk associated with Tamiflu." It recommends that close monitoring of patients begin immediately after starting treatment with the drug.

The changes bring the U.S. label more in line with the Japanese one, which already warned that such abnormal behavior could occur. The previous FDA-approved label mentioned only that "seizure and confusion" had been seen in some patients.

Tamiflu is made by the Swiss pharmaceutical company Roche Holding AG. Roche spokesman Terence Hurley said there was no evidence the drug caused the rarely occurring adverse events. Both Roche and the FDA also said that severe cases of the flu can spark the abnormal behavior flagged in the updated label.

Furthermore, the FDA acknowledged that stopping treatment with Tamiflu could actually harm influenza patients if the virus is the cause of delirium, hallucinations and other abnormal behavior, such as aggression and suicidal thoughts.

Health officials have been sensitive about taking any action that might dissuade people from taking Tamiflu, since the drug could play an important role in an outbreak of bird flu. The drug doesn't prevent flu but can reduce the length and severity of its symptoms.

Previously, Roche has cited studies from the U.S. and Canada that show the death rate of influenza patients who took Tamiflu was far below those who did not. Still, the number of reports of bizarre behavior is increasing.

The 103 new cases occurred between Aug. 29, 2005, and July 6, 2006. The tally marks a sharp increase when compared with the 126 similar cases logged over more than five years between the drug's approval in 1999 and August 2005, the FDA said.

Even though severe cases of the flu can spark abnormal behavior, the number and nature of the newly reported cases — along with comments from doctors who believe the behavior was associated with the drug — keep the FDA from ruling out Tamiflu as the cause, the agency said.

Tamiflu is one of the few drugs believed effective in treating bird flu, which health officials fear could spark a pandemic should it mutate into a form easily passed from human to human.

According to the label, Tamiflu is for the treatment of uncomplicated acute illness due to flu in patients 1 year and older who have shown symptoms for no more than two days.

Related Content

KLAS PACS Report Rates Carestream Health A Top Performer
News | PACS | January 23, 2018
January 23, 2017 – Carestream Health’s Radiology PACS (picture archiving and communication system) module of the...
Technology | PACS | January 22, 2018
QualiTest Group recently announced its improved Virtual Radiology Environment (VRE) testing solution for picture...
Technology | PACS Accessories | January 03, 2018
January 3, 2018 — medQ Inc. recently announced the launch of its Q/ris MIPS Reporting module.
News | Enterprise Imaging | December 21, 2017
Vital Images showcased enhancements to its enterprise imaging solutions at the Radiological Society of North America (...
Videos | Artificial Intelligence | December 21, 2017
ITN and DAIC Editor Dave Fornell shows several examples of how vendors are incorporating AI, deep learning algorithms
Medexprim's Radiomics Enabler Goes Open Source
Technology | PACS Accessories | December 06, 2017
December 6, 2017 — Medexprim announced its Radiomics Enabler, meant to enhance medical images archives for research,
How to allow legacy PACS systems to use a global worklist even with older, disparate PACS systems. Carestream.
Sponsored Content | Whitepapers | PACS | December 06, 2017
Myth: Legacy PACS systems in an M&A environment can not support a global worklist.
Ikonopedia and Konica Minolta Showcase Integrated Breast Imaging Workflow and Reporting at RSNA
News | Breast Imaging | December 05, 2017
Ikonopedia and Konica Minolta Healthcare Americas Inc. showcased integrated breast imaging workflow and reporting at...
Ambra Health Joins Google Cloud Technology Partner Program
News | PACS Accessories | December 05, 2017
December 4, 2017 — Ambra Health recently announced a new relationship with Google Cloud.
Fujifilm Introduces Artificial Intelligence Initiative for U.S. Market at RSNA 2017
News | Artificial Intelligence | December 04, 2017
December 4, 2017 — Fujifilm Medical Systems U.S.A. Inc.
Overlay Init